American Technology Research Initiates Coverage On Pfizer (PFE) With A Buy
Tweet
Share
E-mailGet Alerts PFE Hot Sheet
Price: $27.05 +1.65%
Rating Summary:
14 Buy, 18 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Rating Summary:
14 Buy, 18 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
Today, American Technology Research initiates coverage on Pfizer (NYSE: PFE) with a Buy and a $24 price target, which is 34% upside from here.
Am Tech said following last week's patent settlement with Ranbaxy Labs on
Lipitor, extending the franchise to end of 2011, AmTech has increased confidence in Pfizer's ability to fund its 7.1% dividend and an extended share buy-back program. Am Tech also said it believes Pfizer will support its late-stage R&D efforts, and seek acquisition opportunities to help lessen the Lipitor fall off in 2012.
Am Tech believes Pfizer is significantly undervalued and will likely rise from here.
Pfizer Inc. is a research-based, global pharmaceutical company.
Am Tech said following last week's patent settlement with Ranbaxy Labs on
Lipitor, extending the franchise to end of 2011, AmTech has increased confidence in Pfizer's ability to fund its 7.1% dividend and an extended share buy-back program. Am Tech also said it believes Pfizer will support its late-stage R&D efforts, and seek acquisition opportunities to help lessen the Lipitor fall off in 2012.
Am Tech believes Pfizer is significantly undervalued and will likely rise from here.
Pfizer Inc. is a research-based, global pharmaceutical company.
You May Also Be Interested In
Create E-mail Alert Related Categories
Analyst Comments, Insiders' BlogRelated Entities
American Technology ResearchSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
